Novartis AG
SWXNOVN enters the final stretch before its July 21 Q2 results on a quiet but genuinely divergent note — up 3.1% on the week while most of its closest peers are in the red. The outperformance stands out against a mixed backdrop in large-cap European pharma. AZN added less than 1% on the week. GSK dropped 1.7%, BMY fell 2.7%, and…
NOVN cost to borrow surges to 1.89% — up 191% in one week from 0.65%, signaling acute scarcity of borrowable shares.
Snapshot as of 6 Aug 2026
A new long-form analysis for NOVN this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumNOVN enters the final stretch before its July 21 Q2 results on a quiet but genuinely divergent note — up 3.1% on the week while most of its closest peers are in the red. The outperformance stands out against a mixed…
Novartis heads into the second week of June down 4.6% on the week, closing at CHF 113.00 — yet today's news flow is pulling hard in the other direction. The week's sharpest tension is the gap between a softening share…
NOVN enters the week down 8% over the past month, closing Tuesday at CHF 113.54. The most striking tension here is the gap between insider behaviour — persistent and sizeable selling — and an analyst community that…
NOVN arrives at its Q1 2026 results today with one of the most striking setup features being the near-complete retreat of short sellers over the past six weeks. Short interest has collapsed. The SI % of free float has…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NOVN — free to start on ORTEX.
Sign up for free →Open NOVN on ORTEX